Falecalcitriol

• CAT Number: I005019
• CAS Number: 83805-11-2
• Molecular Formula: C27H38F6O3
• Molecular Weight: 524.58
• Purity: ≥95%
• Target: VD/VDR
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IUPAC Name: (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-7,7,7-trifluoro-6-hydroxy-6-(trifluoromethyl)heptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
• InChI: InChI=1S/C27H38F6O3/c1-16(6-4-13-25(36,26(28,29)30)27(31,32)33)21-10-11-22-18(7-5-12-24(21,22)3)8-9-19-14-20(34)15-23(35)17(19)2/h8-9,16,20-23,34-36H,2,4-7,10-15H2,1,3H3/b18-8+,19-9-/t16-,20-,21-,22+,23+,24-/m1/s1
• InChIKey: XPYGGHVSFMUHLH-UUSULHAXSA-N
• SMILES: C[C@H](CCCC(C(F)(F)F)(C(F)(F)F)O)[C@H]1CC[C@@H] [C@@]1(CCC/C2=CC=C/3C[C@H](C[C@@H](C3=C)O)O)C

Falecalcitriol (Cat.No:I005019) is a synthetic analog of calcitriol, the active form of vitamin D. It is used in the treatment of secondary hyperparathyroidism associated with chronic kidney disease. Falecalcitriol helps regulate calcium and phosphorus levels in the body, promoting bone health and mitigating the effects of renal dysfunction. Consultation with a healthcare professional is advised for proper usage and dosage guidelines.

Reference

1:Comparison of oral falecalcitriol and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism: a randomized, crossover trial. Ito H, Ogata H, Yamamoto M, Takahashi K, Shishido K, Takahashi J, Taguchi S, Kinugasa E.Clin Nephrol. 2009 Jun;71(6):660-8. PMID: 19473635 2:Falecalcitriol for conventional vitamin D therapy-resistant secondary hyperparathyroidism in a continuous ambulatory peritoneal dialysis patient. Tokunaga M, Tamura M, Kabashima N, Serino R, Shibata T, Matsumoto M, Miyamoto T, Miyazaki M, Furuno Y, Takeuchi M, Abe H, Okazaki M, Otsuji Y.Clin Nephrol. 2008 May;69(5):393-4. No abstract available. PMID: 18538106 3:[Long-term suppressive effect of falecalcitriol on parathyroid hormone secretion in secondary hyperparathyroidism in hemodialysis patients]. Iwao Y, Yamaguchi Y, Fujii K, Toba Y, Asada M, Nagano N, Yamamoto H, Hyoma K, Yamada S, Hirano H, Tone Y, Ohtani H, Saika Y, Fujii R.Clin Calcium. 2006 May;16(5):847-51. Japanese. PMID: 16679628 4:[Falecalcitriol as a new therapeutic agent for secondary hyperparathyroidism]. Morii H.Clin Calcium. 2005 Jan;15(1):29-33. Review. Japanese. PMID: 15632470 5:[Pharmacological action and clinical effects of falecalcitriol, a highly potent derivative of active vitamin D3]. Ohtsuka N, Urayama K.Nihon Yakurigaku Zasshi. 2002 Dec;120(6):427-36. Review. Japanese. PMID: 12528474 6:In vivo and in vitro pharmacokinetics and metabolism studies of 26,26,26,27,27,27-F6-1,25(OH)2 vitamin D3 (Falecalcitriol) in rat: induction of vitamin D3-24-hydroxylase (CYP24) responsible for 23S-hydroxylation in target tissues and the drop in serum levels. Komuro S, Sato M, Kanamaru H, Kaneko H, Nakatsuka I, Yoshitake A.Xenobiotica. 1999 Jun;29(6):603-13. PMID: 10426559 7:Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism. Akiba T, Marumo F, Owada A, Kurihara S, Inoue A, Chida Y, Ando R, Shinoda T, Ishida Y, Ohashi Y.Am J Kidney Dis. 1998 Aug;32(2):238-46. PMID: 9708607